Corcept to Evaluate Safety and Dosage of Nenocorilant in Combination with Nivolumab in a Phase 1b/2 Clinical Trial for Advanced Solid Tumors
Maximizing Immunotherapy Response by Blocking Cortisol
Corcept Therapeutics is conducting a Phase 1b/2 clinical trial (NCT07276373) to evaluate the combination therapy of its selective glucocorticoid receptor antagonist (SGRA), Nenocorilant (CORT125236), with Bristol Myers Squibb's immune checkpoint inhibitor, Nivolumab (Odivo), in patients with advanced solid tumors. Cortisol, a stress hormone, induces immune evasion in the tumor microenvironment. Nenocorilant selectively blocks the glucocorticoid receptor (GR), preventing the depletion of CD8+ T cells. This combination therapy aims to restore responsiveness in solid tumor patients who are resistant to immunotherapy.
Determining Optimal Dosage Through Sequential Dose Escalation
This trial is designed to assess safety and establish the maximum tolerated dose (MTD) and optimal dosage. The study is conducted in an open-label manner, with patients divided into cohorts receiving Nenocorilant at doses of 200mg, 300mg, and 400mg. Nivolumab is administered at 240mg every two weeks in combination. After three months of treatment, the Nivolumab dose can be flexibly adjusted to 480mg every four weeks based on patient tolerance, enhancing long-term treatment convenience.
Expanding the Solid Tumor Pipeline Following the Approval of Lifyorli
In March 2026, Corcept received FDA approval for Lifyorli (relacorilant), a selective receptor antagonist, for the treatment of platinum-resistant ovarian cancer, demonstrating the clinical efficacy of its platform. Nenocorilant, its follow-up pipeline product, represents Corcept's core growth strategy, expanding beyond combination with existing chemotherapy to include combinations with immunotherapies. The success of Lifyorli has boosted confidence in the clinical program, and industry attention is focused on the performance of the next-generation pipeline.
Enhancing Commercial Value by Overcoming Immune Checkpoint Inhibitor Resistance
The global immune checkpoint inhibitor market is experiencing rapid growth, projected to reach $82 billion by 2026. However, more than 70% of patients still do not respond or develop resistance. If Nenocorilant demonstrates safety and efficacy in overcoming resistance in this clinical trial, it will provide an alternative for many cancer patients. This will be a crucial opportunity for Corcept to establish itself as a leader in the cancer resistance market and maximize the value of its pipeline.
Corcept's Phase 1b/2 clinical trial of Nenocorilant in combination therapy represents a mid- to long-term strategy to capture exclusive commercial value in the $82 billion global immune checkpoint inhibitor market by targeting non-responsive patients. Following the FDA approval of Lifyorli in March 2026, this trial significantly expands the indications for the next-generation selective glucocorticoid receptor antagonist (SGRA) platform, attracting attention from researchers and investors. In the short term, the company's value will be reassessed based on the results of the safety and dosage cohort (200mg to 400mg) studies. In the long term, demonstrating superior response rates compared to existing single-agent immunotherapies will be key to securing commercial success. Given that competing pipelines with similar mechanisms, such as ORIC-101, have been discontinued in early stages, the clinical data that Corcept will present will be a critical milestone in establishing its leading position in this field.
Source: ClinicalTrials.gov (api_ct)